Literature DB >> 29101206

Knockdown of TP53 in ASXL1 negative background rescues apoptotic phenotype of human hematopoietic stem and progenitor cells but without overt malignant transformation.

Susan Hilgendorf1, Edo Vellenga2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29101206      PMCID: PMC5792287          DOI: 10.3324/haematol.2017.173922

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Authors:  D A Sallman; R Komrokji; C Vaupel; T Cluzeau; S M Geyer; K L McGraw; N H Al Ali; J Lancet; M J McGinniss; S Nahas; A E Smith; A Kulasekararaj; G Mufti; A List; J Hall; E Padron
Journal:  Leukemia       Date:  2015-10-30       Impact factor: 11.528

2.  Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells.

Authors:  Susan Hilgendorf; Hendrik Folkerts; Jan Jacob Schuringa; Edo Vellenga
Journal:  Exp Hematol       Date:  2016-09-08       Impact factor: 3.084

3.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

Review 5.  The genetic basis of myelodysplasia and its clinical relevance.

Authors:  Mario Cazzola; Matteo G Della Porta; Luca Malcovati
Journal:  Blood       Date:  2013-10-17       Impact factor: 22.113

6.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  ASXL1 plays an important role in erythropoiesis.

Authors:  Hui Shi; Shohei Yamamoto; Mengyao Sheng; Jie Bai; Peng Zhang; Runze Chen; Shi Chen; Lihong Shi; Omar Abdel-Wahab; Mingjiang Xu; Yuan Zhou; Feng-Chun Yang
Journal:  Sci Rep       Date:  2016-06-29       Impact factor: 4.379

8.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

9.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Authors:  Omar Abdel-Wahab; Mazhar Adli; Lindsay M LaFave; Jie Gao; Todd Hricik; Alan H Shih; Suveg Pandey; Jay P Patel; Young Rock Chung; Richard Koche; Fabiana Perna; Xinyang Zhao; Jordan E Taylor; Christopher Y Park; Martin Carroll; Ari Melnick; Stephen D Nimer; Jacob D Jaffe; Iannis Aifantis; Bradley E Bernstein; Ross L Levine
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

10.  Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.

Authors:  Jiajun Zhu; Morgan A Sammons; Greg Donahue; Zhixun Dou; Masoud Vedadi; Matthäus Getlik; Dalia Barsyte-Lovejoy; Rima Al-awar; Bryson W Katona; Ali Shilatifard; Jing Huang; Xianxin Hua; Cheryl H Arrowsmith; Shelley L Berger
Journal:  Nature       Date:  2015-09-02       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.